Research in Lung Aging and Critical Care at NHLBI

Lisa Postow, Ph.D.
Program Officer
Division of Lung Diseases
National Heart, Lung, and Blood Institute

ATS Aging Interest Group
June 23, 2021
Interest of NHLBI in Lung Aging Research

- What is “normal lung aging”?
- How do mechanisms of lung aging relate to (non-cancer) disease pathobiology?
- How can we treat and care for patients with aging-related lung diseases?

Ongoing program funded by NHLBI and NIA to understand the molecular landscape of lung aging:
https://www.youtube.com/watch?v=3GVn4SBzTqQ
How do “hallmarks of aging” in the lung lead to disease?

Aging

- Cell types
- Exposures
- Behaviors
- Infection
- Genetics
- Lung structure

Disease

- COPD
- IPF
- Pulmonary Hypertension
- ARDS/ALI
- Pneumonia
- HIV
- COVID-19

López-Otín et al, Cell Volume 153, Issue 6, 6 June 2013, Pages 1194-1217
Lung function decline through the life course

FEV₁ in percent of predicted maximally attained value

- TR1: Normal
- TR2: Small lungs but no COPD
- TR3: Normal initial FEV₁ with rapid decline leading to COPD
- TR4: Small lungs leading to COPD

Age range under observation

Age (years)

Recommendations:

- Use aged animals for the study of aging-related lung diseases
- Understand mechanisms of normal aging in the lung
- Develop integrative systems-based platforms that can incorporate multi-omics data sets of the aging lung
- Understand why hallmarks of aging can lead to different phenotypes and diseases (why are both COPD and IPF diseases of aging despite distinct mechanisms)
Recommendations:

- Identify biomarkers for senescent cells of different cell types and biomarkers of senescence that results from different types of inducers.

- Identify the role of different senescent cell type in senescence-associated diseases of the lung such as IPF and COPD.

- Develop cell type-specific senolytics and senomorphics as well as other methods for clearing senescent cells, including immunotherapies.

- Use NIH-funded aging cohorts to better understand the role of aging in lung diseases.
Recommendations:

- Understand the clinical, physiological, and biological underpinnings of adult pulmonary critical care heterogeneity and disease
- Optimize preclinical models by incorporating comorbidities, cointerventions, and organ failure and support
- Use adaptive and platform clinical study designs
- Incorporate measurement of long-term patient-important outcomes and potential surrogate outcomes
NHLBI/NIGMS ARDS, Pneumonia, and Sepsis Phenotyping Consortium

- Notices of Intent to Publish FOAs for Clinical Centers and Coordinating Center: March 17, 2021
- Estimated FOA publication date: January 14, 2022
- Cooperative multi-site Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium (APS Consortium)
- Prospective, longitudinal observational study with common data and biospecimen collection of 5,000 hospitalized adults with ARDS, pneumonia, or sepsis from hospitalization to 1 year
- Approximately half of the surviving participants will have follow-up at 3, 6, and 12 months
- Inquiries to: Lora Reineck (Lora.Reineck@nih.gov)
Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)

Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases

Notice of Special Interest: Advancing the Science of Geriatric Palliative Care
Other relevant NOSIs and FOAs

- Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)

- Notice of Special Interest (NOSI): Heart, lung, blood and sleep focused ancillary studies to large ongoing clinical studies

- Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)

- Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)